Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon Nov 29, 2022 10:31pm
238 Views
Post# 35138569

RE:Enrique and Eoghan : help please

RE:Enrique and Eoghan : help please

The 1st chart is CR at any time point  23 patients reached CR at 90 days, and 3 got CR at later time points, hence the difference vs 2nd chart is 23 at 90 days ( doesn't include those from later time points. )  Safety has been met with flying colours too 100%.    Looks great and improving exactly as expected.  Seems to be very predictable so far as we see in latest 5 newly evaluable patients where 4 out of 5 are CR with 1 single treatment and 1 seems to be potentialy PR.  That is 80% CR on those 5 after 1 single treatment on patients who failed standard of care and would have required Bladder removal. Cancer free and keep your bladder.  Seems Damn good IMHO 


N0taP00p wrote: The note under table 1 says "CR was achieved as follows: 23 patients at 90 days, 1 patient at 180 days and 2 patients at 270 days."  This is for primary objective.  How does this align with the Table 2  CR numbers for the 90, 180 and 270 columns?  

Second, looks like the safety objective is met 100% this time. No additional eval needed. Right?

Third, they have more than the needed 25 at 450 days and it's already better than keytruda.  Can you please give them your permission to submit?

Last, any idea how much money they have left in the tank?  Thanks for your inputs as always! 




 

<< Previous
Bullboard Posts
Next >>